Wrap-Up

The TROPiCS-02 study aims to confirm optimal treatment choice in patients with hormone receptor–positive/HER2-negative metastatic breast cancer whose disease progresses after having received endocrine therapy (ET) plus cyclin-dependent kinase (CDK)4/6 inhibitor. Read More ›

Wrap-Up

DESTINY-Breast04 Compared T-DXd with TPC in Patients with HER2-Low Breast Cancer

ASCO 2022 – Wrap-Up

DESTINY-Breast04 is the first trial comparing outcomes with trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients with HER2-low metastatic breast cancer treated with 1 or 2 prior lines of chemotherapy. Read More ›

Wrap-Up

Finding Your Strength Through Knowledge: Proceedings from the San Antonio Breast Cancer Symposium

SABCS 2021 – Wrap-Up

Several novel breast cancer therapies have come onto the market in recent years, significantly changing the breast cancer landscape, specifically in the metastatic setting. The Pathways Heart Study has looked at cardiovascular outcomes and risk variables from breast cancer treatments. A number of breast cancer risk factors as well as the benefits of physical exercise and aspirin use among breast cancer survivors are discussed in this review. Read More ›

Wrap-Up

Updated Outcomes of Tucatinib versus Placebo Added to Trastuzumab and Capecitabine (HER2CLIMB) in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer with Brain Metastases

SABCS 2021 – Wrap-Up

Tucatinib added to trastuzumab and capecitabine resulted in a substantial and permanent improvement of progression-free survival and overall survival for all patients with HER2-positive metastatic breast cancer with brain metastases, as confirmed by results from the HER2CLIMB study. Read More ›

Videos Wrap-Up

Finding Your Strength Through Knowledge

By Sharon Gentry, RN, MSN, AOCN, CBCN, HON-ONN-CG

SABCS 2021 – Wrap-Up

Sharon Gentry, a Breast Cancer Nurse Navigator in Winston-Salem, NC, shares topics presented at the 2021 San Antonio Breast Cancer Symposium to help empower patients with breast cancer. Read More ›

Wrap-Up

Results from the I-SPY 2 Trial of Tucatinib plus Paclitaxel + Pertuzumab + Trastuzumab Followed by Doxorubicin/Cyclophosphamide in High-Risk HER2-Positive Stage II/III Breast Cancer

SABCS 2021 – Wrap-Up

Tucatinib-containing therapy resulted in a tumor volume reduction of >80%. Tucatinib was found to be highly effective when combined with paclitaxel plus trastuzumab plus pertuzumab. Read More ›

Wrap-Up

A Review of the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Patients with HER2-Positive Breast Cancer with or without Brain Metastases

SABCS 2021 – Wrap-Up

Tyrosine kinase inhibitor (TKI) treatments show equal overall survival and progression-free survival (PFS) benefits in patients with HER2-positive breast cancer with and without brain metastases. Read More ›

Wrap-Up

Intracranial Efficacy of Tucatinib, Palbociclib, and Letrozole in Patients with Hormone Receptor–Positive, HER2-Positive Breast Cancer with Brain Metastases

SABCS 2021 – Wrap-Up

The combination regimen of tucatinib, palbociclib, and letrozole in patients with hormone receptor–positive, HER2-positive breast cancer with brain metastases demonstrates an improved central nervous system progression-free survival in a small group of patients. Read More ›

Wrap-Up

Safety and Efficacy of a Tucatinib-Trastuzumab-Capecitabine Combination Treatment for Leptomeningeal Metastases in HER2-Positive Breast Cancer

SABCS 2021 – Wrap-Up

Tucatinib-trastuzumab-capecitabine combination therapy has been shown to double the overall survival in patients with HER2-positive breast cancer with leptomeningeal metastases. Read More ›

Wrap-Up

Weight Gain in Breast Cancer Patients During Adjuvant Endocrine Therapy Linked to Menopausal Status

ASCO 2021 – Breast Cancer: Wrap-Up

Improved understanding of potential risk factors associated with weight gain will allow identification of at-risk patients and intervention for improved outcomes. Read More ›

Wrap Ups

Page 2 of 3